Media headlines about Juniper Pharmaceuticals (NASDAQ:JNP) have been trending somewhat positive on Thursday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Juniper Pharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 45.9914304759004 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of analysts have issued reports on the stock. ValuEngine cut shares of Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital started coverage on shares of Juniper Pharmaceuticals in a research report on Tuesday, January 2nd. They set a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Juniper Pharmaceuticals in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $23.00.
Juniper Pharmaceuticals (NASDAQ:JNP) traded down $0.10 on Thursday, hitting $5.90. 29,524 shares of the stock traded hands, compared to its average volume of 77,653. The company has a market cap of $63.98, a price-to-earnings ratio of 9.83 and a beta of 0.03. The company has a current ratio of 2.00, a quick ratio of 1.68 and a debt-to-equity ratio of 0.08. Juniper Pharmaceuticals has a fifty-two week low of $3.65 and a fifty-two week high of $6.40.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/12/juniper-pharmaceuticals-jnp-getting-somewhat-favorable-media-coverage-analysis-finds.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.